NEW YORK: The wrenching selloff in US high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed next week.
First-quarter earnings estimates have fallen sharply as many companies have blamed the brutal winter for weak outlooks.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
